Bausch + Lomb (NYSE:BLCO) Given "Buy" Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Bausch + Lomb (NYSE:BLCO - Free Report) in a research note published on Tuesday,Benzinga reports. They currently have a $23.00 price target on the stock. HC Wainwright also issued estimates for Bausch + Lomb's Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.23 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.27 EPS and FY2025 earnings at $0.91 EPS.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley downgraded Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 target price for the company. in a report on Monday, December 2nd. Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Thursday, January 16th. Needham & Company LLC reiterated a "hold" rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Royal Bank of Canada lowered their target price on Bausch + Lomb from $23.00 to $22.00 and set an "outperform" rating for the company in a report on Wednesday, January 29th. Finally, Stifel Nicolaus lowered their target price on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating on the stock in a research report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $19.83.

Bausch + Lomb Trading Down 0.9 %

Shares of Bausch + Lomb stock traded down $0.15 during midday trading on Tuesday, reaching $15.75. The company had a trading volume of 589,710 shares, compared to its average volume of 684,586. The stock has a fifty day moving average price of $17.36 and a 200 day moving average price of $18.13. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The firm has a market cap of $5.55 billion, a PE ratio of -17.30, a P/E/G ratio of 2.17 and a beta of 0.46. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.02. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.34% and a negative net margin of 6.62%. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 earnings per share. On average, equities analysts anticipate that Bausch + Lomb will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On Bausch + Lomb

A number of institutional investors and hedge funds have recently bought and sold shares of BLCO. Alberta Investment Management Corp raised its position in Bausch + Lomb by 36.0% in the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company's stock valued at $54,328,000 after buying an additional 796,400 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Bausch + Lomb in the 4th quarter valued at $14,122,000. King Street Capital Management L.P. purchased a new stake in Bausch + Lomb in the 3rd quarter valued at $14,122,000. Arrowstreet Capital Limited Partnership raised its position in Bausch + Lomb by 51.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after buying an additional 414,138 shares during the last quarter. Finally, Barclays PLC purchased a new stake in Bausch + Lomb in the 3rd quarter valued at $5,797,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.